Johnson & Johnson’s Darzalex is already on track to nab a second multiple myeloma nod in newly diagnosed patients in the U.S., but its journey with England’s cost watchdog hasn’t been so smooth. More: NICE limits coverage of Johnson & Johnson, Takeda’s
read moreThe plant in India where Biocon makes the biosimilars it shares with Mylan was given a clean bill of health by the FDA last year—but not for long. The FDA posted a new Form 483 for the facility Tuesday following
read moreEli Lilly has new data that could help expand Cyramza’s lung cancer footprint. But if it does win approval to treat EGFR-mutated tumors, it’ll face a tough field of competitors. More: Lilly's Cyramza scores in targeted lung cancer—but major competition
read moreSome Big Pharma CEOs got eye-popping pay raises last year, even if their companies blundered. Sanofi chief Olivier Brandicourt wasn’t one of them. He took a pay cut, in fact, as U.S. sales of the company’s flagship diabetes products continued
read moreAdults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting. More: SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma Source:
read moreTakeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used biologics for the disease. More: Takeda’s Entyvio bests AbbVie’s Humira
read more© 1994 - 2026 B.M. Pharmaceuticals